Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer

Details for Australian Patent Application No. 2004209579 (hide)

Owner Lorus Therapeutics Inc.

Inventors Wright, Jim A.; Young, Aiping H.

Agent Lesicar Perrin

Pub. Number AU-B-2004209579

PCT Pub. Number WO2004/070033

Priority 60/320,240 31.05.03 US; 60/448,117 20.02.03 US; 2,418,605 10.02.03 CA

Filing date 10 February 2004

Wipo publication date 19 August 2004

Acceptance publication date 4 March 2010

International Classifications

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 38/00 (2006.01) Medicinal preparations containing peptides

Event Publications

25 August 2005 PCT application entered the National Phase

  PCT publication WO2004/070033 Priority application(s): WO2004/070033

17 May 2007 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 05 Apr 2007

23 August 2007 Assignment before Grant

  GeneSense Technologies Inc The application has been assigned to Lorus Therapeutics Inc.

4 March 2010 Application Accepted

  Published as AU-B-2004209579

15 July 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004209596-A steam turbine system

2004209578-Method to detect prostate cancer in a sample